Stock Analysis
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis
Xeris Biopharma Holdings, Inc. (XERS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Xeris Biopharma Holdings, Inc. (XERS) currently has an AIQ Score of 78/100, indicating a bullish setup. Momentum is the strongest factor at 98/100. Risk is the weakest current factor at 55/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
XERS at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $16.66 |
| AIQ Score | 78/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $3.01B |
| P/E Ratio (TTM) | -415.46 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $0.06 |
| Revenue (Q3 FY2026) | $107.23M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.07 |
| Volume | 3.4M |
| 52-week range | $5.25-$16.88 |
| RSI 14 | 85.42 |
| 50-Day SMA | $10.40 |
| 200-Day SMA | $7.83 |
| Analyst Price Target | $15.00 |
| Next Earnings | Mar 1, 2027 |
XERSXeris Biopharma Holdings, Inc.
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum98
- Value68
- Quality71
- Risk resilience55
- Sentiment—
XERS Stock Analysis Summary
Xeris Biopharma Holdings, Inc. (XERS) currently has an AIQ Score of 78/100, indicating a bullish setup. Momentum is the strongest factor at 98/100. Risk resilience is the weakest current factor at 55/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, XERS has AIQ Score of 78/100 with Momentum base of 98/100 and fading Risk resilience at 55/100. Wait for component alignment before adding exposure.
Momentum (98/100) leads while Risk resilience (55/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.06% stock move · XERS classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is XERS Bullish or Bearish Right Now?
XERS currently has a bullish overall setup. Momentum is the strongest factor at 98/100, while Risk Resilience is weakest at 55/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 71/100.
- - Momentum is constructive at 98/100.
- - Price is +60.12% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (37 vs 9).
- - Analyst target implies -9.96% downside from the latest quote.
Current Consensus
XERS's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 0 neutral, and 9 sell votes. XERS's 14-day RSI is 85.42, which places the stock in an overbought momentum range. XERS's beta is 0.07, indicating lower market sensitivity than the broad market.
What Changed in XERS?
The largest recent change in XERS is Momentum moving up by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the XERS Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
XERS Decision Framework
Public evidence layers, setup checks, and risk context for Xeris Biopharma Holdings, Inc..
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis
Xeris Biopharma Holdings, Inc. has an AIQ Score of 78/100 in a Bullish regime. Momentum is strongest at 98/100. Beta is 0.07, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | XERS is in a Bullish AIQ regime with score 78/100. |
| Signal Conflict | The primary conflict is that momentum leads at 98/100 while risk lags at 55/100. |
| Factor Evidence | Momentum 98/100 · Value 68/100 · Quality 71/100 · Risk 55/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 98/100.
Momentum is 98/100 and RSI (14) is 85.4.
XERS is in a Bullish regime at 78/100.
Risk factor is 55/100 with beta 0.07 and annual volatility 56.97%.
Current conflict: momentum leads at 98/100 while risk lags at 55/100.
XERS Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
XERS Fundamentals
XERS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
XERS Technical Analysis
XERS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
XERS Stock Catalysts
Track XERS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
XERS Dividend Analysis
XERS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
XERS Financial Data
XERS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
XERS Risk Analysis
XERS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
XERS Stock News
XERS stock news, market tone, recent headlines, and catalyst context.
XERS vs Biotechnology Peers
Current peer cohort: XERS · ZBIO · ZYME · ABCL · ABSI. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| XERS Current stock | 78/100 | 68/100 | 98/100 | 55/100 | 1.67 | 56.97% | Current |
| ZBIO Zenas BioPharma, Inc. | 47/100 | 33/100 | 78/100 | 39/100 | 0.26 | 95.33% | XERS vs ZBIO |
| ZYME Zymeworks Inc. | 68/100 | 66/100 | 78/100 | 61/100 | 0.84 | 54.03% | XERS vs ZYME |
| ABCL AbCellera Biologics Inc. | 64/100 | 47/100 | 89/100 | 34/100 | 1.73 | 85.28% | XERS vs ABCL |
| ABSI Absci Corporation | 53/100 | — | 85/100 | 30/100 | 1.58 | 104.15% | XERS vs ABSI |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for XERS: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching XERS
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for XERS
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
XERS Stock FAQ
What is XERS stock price today?
Xeris Biopharma Holdings, Inc.'s current stock price is $16.66. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is XERS bullish or bearish right now?
XERS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is XERS's market cap?
XERS's market cap is $3.01B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is XERS's current P/E ratio?
XERS's current P/E ratio is -415.46 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is XERS's RSI?
XERS's 14-day RSI is 85.42 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is XERS above its 50-day and 200-day moving averages?
XERS is 60.12% from its 50-day SMA and 112.76% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is XERS's next earnings date?
XERS's next earnings date is currently listed as Mar 1, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does XERS pay a dividend?
XERS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.